Centrifuged FMT products consistently exhibit the lowest median log₁₀ drop of CFU/g following freezing and lyophilization. In contrast, unprocessed feces exhibited the g... حسب Nina K. Randolph (21030732)

Scenario 2. Advanced patient with STAT-ON™. حسب Daniel Rodriguez-Martin (22411006)

"…While medication costs may increase, overall direct healthcare expenses decrease, leading to net savings. As an example, the study estimates potential cost reductions of up to €137.8 million in Germany and €19 million in Sweden when STAT-ON™ is used to detect advanced PD symptoms. …"

Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras حسب Charles W. Parry (20966154)

Parvalbumin-positive interneurons (PV-INs) in perilesional tissue respond to optogenetic stimulation and are involved in voluntary movement, but show a decreased firing rate. حسب Livia Vignozzi (22430567)

Application to actual brain network functional states. حسب Remy Ben Messaoud (20521877)

Effect of advanced chelate technology-based trace minerals on bone morphology and mineral contents observed in broiler chickens challenged with heat stress. حسب Taher Mohammadizad (19786989)

الموضوعات:

Single-driver controllability of brain networks. حسب Remy Ben Messaoud (20521877)

The growth of co-transformed cells in the peritoneal cavity alters viral gene expression to mirror that of PEL cell lines. حسب Mitchell Hayes (5334887)

The growth of co-transformed cells in the peritoneal cavity alters their cellular gene expression to mirror that of PEL biopsies. حسب Mitchell Hayes (5334887)

Co-infected cells express both KSHV and EBV genes <i>in vitro</i> necessary for their survival and growth. حسب Mitchell Hayes (5334887)

Effect of advanced chelate technology-based trace minerals on serum antioxidant status and hormone profile observed in broiler chickens challenged with heat stress. حسب Taher Mohammadizad (19786989)

الموضوعات:

Co-transformed cells grow preferentially as tumors in peritoneal cavities. حسب Mitchell Hayes (5334887)

Technical properties of tested UASs. حسب Marc Roswag (20598443)

"…Our results support this hypothesis, because multicopter flights have a highly significant negative impact on bat activity levels with a medium effect size, particularly for the Myotini (<i>P</i> < 0.001, <i>d</i>_<i>m</i> = 0.54) and Nyctaloid group (<i>P</i> < 0.001, <i>d</i>_<i>n</i> = 0.55) and a small effect size for the Pipistrelloid group (<i>P</i> < 0.001, <i>d</i>_<i>p</i> = 0.36). …"

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …"

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …"

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …"

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …"

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …"

Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …"

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). The addition of bevacizumab to this regimen (PD-1/PD-L1 inhibitors+bevacizumab+chemotherapy [PIBC]) remains controversial regarding its potential to enhance antitumor efficacy in clinical practice. …"